J. Safra Asset Management’s Royalty Pharma RPRX Stock Holding History

J. Safra Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.9K	Sell	373 -138	-27%	-$7.18K	﹤0.01%	320
2026 Q1	$24.5K	Buy	511 +345	+208%	+$15.1K	﹤0.01%	294
2025 Q4	$6.41K	Hold	166	–	–	﹤0.01%	398
2025 Q3	$5.86K	Buy	166 +1	+0.6%	+$36	﹤0.01%	294
2025 Q2	$5.95K	Hold	165	–	–	﹤0.01%	325
2025 Q1	$5.14K	Buy	165 +139	+535%	+$4.41K	﹤0.01%	311
2024 Q4	$658	Hold	26	–	–	﹤0.01%	318
2024 Q3	$733	Buy	+26	New	+$720	﹤0.01%	279
2023 Q1	–	Sell	-194	Closed	-$7K	–	124
2022 Q4	$7K	Buy	+194	New	+$8.1K	﹤0.01%	52

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Asset Management's RPRX Position: Q2 2026 in Review

J. Safra Asset Management reduced its Royalty Pharma (RPRX) stake by 27% in Q2 2026, selling an estimated $7.18K and leaving 373 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #320.

J. Safra Asset Management first reported a position in RPRX in Q4 2022 and has held it in 9 quarters since. The position peaked at $24.5K in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

J. Safra Asset Management held 373 shares of Royalty Pharma worth $20.9K as of Q2 2026.
J. Safra Asset Management sold 138 Royalty Pharma shares in Q2 2026, an estimated $7.18K.
Royalty Pharma made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #320 holding.
J. Safra Asset Management first reported a position in Royalty Pharma in Q4 2022 and has held it in 9 quarters since.
J. Safra Asset Management's Royalty Pharma position peaked at $24.5K in Q1 2026.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.